KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Shares Repurchased (2016 - 2022)

Pfizer (PFE) has disclosed Shares Repurchased for 11 consecutive years, with $2.0 billion as the latest value for Q4 2022.

  • On a quarterly basis, Shares Repurchased changed N/A to $2.0 billion in Q4 2022 year-over-year; TTM through Oct 2023 was $2.0 billion, a 50.0% decrease, with the full-year FY2022 number at $2.0 billion, changed N/A from a year prior.
  • Shares Repurchased was $2.0 billion for Q4 2022 at Pfizer, roughly flat from $2.0 billion in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $8.9 billion in Q1 2019 to a low of $1.1 billion in Q3 2018.
  • A 3-year average of $4.2 billion and a median of $3.5 billion in 2018 define the central range for Shares Repurchased.
  • Peak YoY movement for Shares Repurchased: rose 21.26% in 2018, then surged 46.21% in 2019.
  • Pfizer's Shares Repurchased stood at $5.0 billion in 2018, then surged by 76.24% to $8.9 billion in 2019, then crashed by 77.44% to $2.0 billion in 2022.
  • Per Business Quant, the three most recent readings for PFE's Shares Repurchased are $2.0 billion (Q4 2022), $2.0 billion (Q2 2022), and $8.9 billion (Q1 2019).